

# TAMIR BIOTECHNOLOGY, INC.

## FORM 8-K

(Current report filing)

Filed 02/04/10 for the Period Ending 01/02/10

Address	300 ATRIUM DRIVE SOMERSET, NJ 08873
Telephone	732-652-4525
CIK	0000708717
Symbol	ACEL
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	07/31

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 2, 2010**

**Alfacell Corporation**

(Exact name of registrant as specified in its charter)

**0-11088**

( Commission File Number )

**Delaware**

(State or other jurisdiction of  
incorporation)

**22-2369085**

(I.R.S. Employer Identification No.)

**300 Atrium Drive, Somerset, NJ 08873**

(Address of principal executive offices, with zip code)

**(732) 652-4525**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 2, 2010 and January 29, 2010, respectively, Donald Conklin and Kuslima Shogen, members of the board of directors of Alfacell Corporation (the “Company”), resigned from the board and committees thereof. The resignations were tendered in accordance with the terms of the Securities Purchase Agreement dated as of October 19, 2009 and filed as Exhibit 10.1 to the Company’s Form 8-K filed with the Securities and Exchange Commission on October 20, 2009.

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 4, 2010

### **ALFACELL CORPORATION**

By: /s/ Charles Muniz

---

Charles Muniz  
President, Chief Executive Officer and Chief  
Financial Officer